LEADER 01734oam  2200493   450 
001 9910715204403321
005 20210518143206.0
035   $a(CKB)5470000002509985
035   $a(OCoLC)1236127609
035   $a(EXLCZ)995470000002509985
100   $a20210204d2020      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act $ereport (to accompany H.R 2374) (Including cost estimate of the Congressional Budget Office)
210  1$a[Washington, D.C.] :$c[U. S. Government Publishing Office],$d2020.
215   $a1 online resource (10 pages)
225 1 $aReport / 116th Congress, 2d session, House of Representatives ;$v116-694
300   $a"December 24, 2020."
320   $aIncludes bibliographical references.
517   $aStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act 
606   $aGeneric drugs$zUnited States
606   $aDrug approval$zUnited States
606   $aDrug approval$2fast
606   $aGeneric drugs$2fast
607   $aUnited States$2fast
608   $aLegislative materials.$2fast
608   $aLegislative materials.$2lcgft
615  0$aGeneric drugs
615  0$aDrug approval
615  7$aDrug approval.
615  7$aGeneric drugs.
801  0$bGPO
801  1$bGPO
801  2$bOCLCO
801  2$bOCLCF
801  2$bDWP
801  2$bGPO
906   $aBOOK
912   $a9910715204403321
996   $aStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act$93480934
997   $aUNINA